202646-80-8
202646-80-8
Chemical Structure
FR194921
- CAS No.: 202646-80-8
- Formula:C23H23N5O
- Molecular Weight:385.46
IUPAC Name: 2-(1-methylpiperidin-4-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-3(2H)-one
InChIKey: YHDRUTMZCJZJAL-UHFFFAOYSA-N
SMILES: O=C1C=CC(C2=C3C=CC=CN3N=C2C4=CC=CC=C4)=NN1C5CCN(CC5)C
Biological Activity: FR194921 is a potent, selective and orally active and cross the blood-brain barrier Adenosine A1 antagonist with Ki value of 6.6, 5400 nM for A1, A2A, respectively. FR194921 shows cognitive-enhancing and anxiolytic activity[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
FR194921 | 99.80% | FR194921 is a potent, selective and orally active and cross the blood-brain barrier Adenosine A1 antagonist with Ki value of 6.6, 5400 nM for A1, A2A, respectively. FR194921 shows cognitive-enhancing and anxiolytic activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Benzpiperylone | Benzpiperylone (KB 95) is a synthetic drug with potent anti-inflammatory properties. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
FK 838 | FK 838 is an adenosine subtype-1 receptor antagonist with potent diuretic activity. FK 838 can be used for the research of cardiovascular disease, such as hypertension . | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
FK 453 | 99.20% | FK 453 (compound 1d) is a potent and selective adenosine A1 receptor antagonist with an IC50 value of 17.2 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ERK Inhibitor II (Negative control) | ERK Inhibitor II (Negative control) is an effective inhibitor of extracellular signal-regulated kinase (ERK). ERK Inhibitor II (Negative control) inhibits the activation of insulin receptor, which can be used in the study of diabetes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
FR 180204 | 99.91% | FR 180204 is an ATP-competitive and selective ERK inhibitor. FR 180204 inhibits ERK1 and ERK2 with IC50s of 0.51 μM (Ki=0.31 μM) and 0.33 μM (Ki=0.14 μM), respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SRI-37240 | 98.29% | SRI-37240 is a potent premature termination codons (PTCs) inhibitor. SRI-37240 suppresses CFTR nonsense mutations. SRI-37240 alters cellular translation termination at PTCs in HEK293T cells. SRI-37240 can also restore CFTR function in primary bronchial epithelial cells when combination with G418. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NUDT5/14 antagonist 1 | 99.69% | NUDT5/14 antagonist 1 (Compound 9) is a selective, dual antagonist for nucleotide diphosphate kinase NUDT5 and NUDT14, with IC50 of 0.27 and 0.16 μM, respectively. NUDT5/14 antagonist 1 binds to Bruton’s tyrosine kinase (BTK) with an IC50 of 0.377 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
FK3453 | 99.98% | FK3453 is a dual adenosine A1/A2 inhibitor and a TSLP inhibitor. FK3453 is also a substrate of aldehyde oxidase (AO). FK3453 can inhibit the production of TSLP and IL-33. FK3453 is useful for research on Parkinson’s disease and allergic disorders. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(S)-Azelastine hydrochloride | (S)-Azelastine hydrochloride, an antihistamine, is a potent and selective histamine 1 (H1) antagonist. (S)-Azelastine hydrochloride can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ibrutinib impurity 11 | 99.89% | Ibrutinib Impurity 11 is an impurity of Ibrutinib (HY-10997). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kuroda S, et al. Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability. Chem Pharm Bull (Tokyo). 2001 Aug;49(8):988-98. [Content Brief]
- [2]. Maemoto T, et al. Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors. J Pharmacol Sci. 2004 Sep;96(1):42-52. [Content Brief]
